Literature DB >> 3044599

Human macrophage maturation and heterogeneity: restricted expression of late differentiation antigens in situ.

R Andreesen1, S Gadd, U Costabel, H G Leser, V Speth, B Cesnik, R C Atkins.   

Abstract

Terminal maturation of human macrophages is an important step for creation of cell diversity amongst site-specific subpopulations and their functional competence in situ. As monocytes undergo differentiation in vitro, they start to express lineage-restricted antigens specific for differentiation stages beyond the blood monocyte level as detected by monoclonal antibodies of the MAX series. We have analyzed the expression of MAX.1, MAX.2, MAX.3 and MAX.11 on exudate-type macrophages from pleural and peritoneal cavity and the alveolar space, as well as on resident and activated tissue macrophages in cryostat sections of spleen, lymph node, tonsil, liver, gut mucosa, skin, placenta, kidney and bone. It was found that "free" macrophages in serous cavities expressed MAX antigens in a heterogenous pattern, whereas none of the organ-specific tissue macrophages subsets did so (with the exception being the weak label of MAX.2 on Kupffer cells). Only during allograft rejection were infiltrating macrophages found to express MAX antigens but not at sites of "non-specific" inflammation or granuloma formation. However, Cyclosporin A treatment seems to suppress the induction of MAX antigen expression on intragraft macrophages. In addition, freshly harvested MAX-negative exudate macrophages converted to the complete Max+ phenotype on further cultivation. Isolated Kupffer cells were able only to express the MAX.2 antigen in culture but still did not react with the MAX.1 and MAX.3 monoclonal antibodies. Some MAX antigens are co-expressed on glomerular mesangial cells, dendritic reticulum cells and placental cells (MAX.1/.11) as well as on capillary endothelium within tissues of active immune response (MAX.2).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044599     DOI: 10.1007/BF00222281

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  55 in total

1.  Mac-1: a macrophage differentiation antigen identified by monoclonal antibody.

Authors:  T Springer; G Galfré; D S Secher; C Milstein
Journal:  Eur J Immunol       Date:  1979-04       Impact factor: 5.532

2.  Monoclonal antibodies to E92, an endothelial cell surface antigen.

Authors:  K L Kaplan; D Weber; P Cook; M Dalecki; L Rogozinski; O Sepe; D Knowles; V P Butler
Journal:  Arteriosclerosis       Date:  1983 Sep-Oct

Review 3.  Current view on the mononuclear phagocyte system.

Authors:  R van Furth
Journal:  Immunobiology       Date:  1982-04       Impact factor: 3.144

4.  Circulating activated suppressor T lymphocytes in aplastic anemia.

Authors:  N C Zoumbos; P Gascón; J Y Djeu; S R Trost; N S Young
Journal:  N Engl J Med       Date:  1985-01-31       Impact factor: 91.245

5.  Biochemical models of gamma-interferon action: altered expression of transferrin receptors on murine peritoneal macrophages after treatment in vitro with PMA or A23187.

Authors:  J E Weiel; D O Adams; T A Hamilton
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

6.  Long-term human peripheral blood monocyte cultures: establishment, metabolism and morphology of primary human monocyte-macrophage cell cultures.

Authors:  S H Zuckerman; S K Ackerman; S D Douglas
Journal:  Immunology       Date:  1979-10       Impact factor: 7.397

7.  The mononuclear phagocyte system of the mouse defined by immunohistochemical localisation of antigen F4/80: macrophages associated with epithelia.

Authors:  D A Hume; V H Perry; S Gordon
Journal:  Anat Rec       Date:  1984-11

8.  Cytotoxic effector cell function at different stages of human monocyte-macrophage maturation.

Authors:  R Andreesen; J Osterholz; K J Bross; A Schulz; G A Luckenbach; G W Löhr
Journal:  Cancer Res       Date:  1983-12       Impact factor: 12.701

9.  In vitro differentiation of human monocytes. Differences in monocyte phenotypes induced by cultivation on glass or on collagen.

Authors:  G Kaplan; G Gaudernack
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

10.  The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80. Relationship between macrophages, Langerhans cells, reticular cells, and dendritic cells in lymphoid and hematopoietic organs.

Authors:  D A Hume; A P Robinson; G G MacPherson; S Gordon
Journal:  J Exp Med       Date:  1983-11-01       Impact factor: 14.307

View more
  5 in total

1.  Characterization of MAX.3 antigen, a glycoprotein expressed on mature macrophages, dendritic cells and blood platelets: identity with CD84.

Authors:  S W Krause; M Rehli; S Heinz; R Ebner; R Andreesen
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

2.  Monocyte macrophage differentiation in vitro: Fibronectin-dependent upregulation of certain macrophage-specific activities.

Authors:  P R Sudhakaran; A Radhika; S S Jacob
Journal:  Glycoconj J       Date:  2007-01       Impact factor: 2.916

3.  Impaired accessory cell function in a human dendritic cell line after human immunodeficiency virus infection.

Authors:  Prarthana Beuria; Houchu Chen; Michael Timoney; Kirk Sperber
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

4.  Inducible transgenes under the control of the hCD68 promoter identifies mouse macrophages with a distribution that differs from the F4/80 - and CSF-1R-expressing populations.

Authors:  Manoj M Pillai; Brian Hayes; Beverly Torok-Storb
Journal:  Exp Hematol       Date:  2009-09-20       Impact factor: 3.084

5.  Mapping of carboxypeptidase m in normal human kidney and renal cell carcinoma: expression in tumor-associated neovasculature and macrophages.

Authors:  Catherine J Denis; Nathalie Van Acker; Stefanie De Schepper; Martine De Bie; Luc Andries; Erik Fransen; Dirk Hendriks; Mark M Kockx; Anne-Marie Lambeir
Journal:  J Histochem Cytochem       Date:  2012-11-19       Impact factor: 2.479

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.